英文字典中文字典


英文字典中文字典51ZiDian.com



中文字典辞典   英文字典 a   b   c   d   e   f   g   h   i   j   k   l   m   n   o   p   q   r   s   t   u   v   w   x   y   z       







请输入英文单字，中文词皆可：

potpie    音标拼音: [p'ɑtp,ɑɪ]

安装中文字典英文字典查询工具!


中文字典英文字典工具:
选择颜色:
输入中英文单字

































































英文字典中文字典相关资料:


  • Yuviwel: Uses, Dosage, Side Effects, Warnings - Drugs. com
    Yuviwel is used to increase linear growth in children 2 years and older with achondroplasia with open epiphyses It is given once-weekly by subcutaneous injection Learn about side effects, the mechanism of action, and administration
  • Yuviwel for Achondroplasia - WebMD
    Yuviwel is an FDA-approved medicine to help improve growth rates in certain people with achondroplasia Here’s how it works
  • Navepegritide Plus Lonapegsomatropin Beneficial in Achondroplasia
    Arm span gains of 9 4 cm in treatment-naive and 7 9 cm in navepegritide-experienced children over 52 weeks surpassed the natural history trend for untreated children with achondroplasia Children with achondroplasia who received 52 weeks of concurrent once weekly navepegritide and lonapegsomatropin
  • FDA Grants Accelerated Approval to Navepegritide for . . .
    The United States (US) Food and Drug Administration (FDA) has granted accelerated approval to navepegritide (YUVIWEL), a once-weekly C-type natriuretic peptide (CNP) analog, to increase linear growth in children aged 2 years and older with achondroplasia and open epiphyses The decision was based on improvements in annualized growth velocity (AGV) from 3 phase 3 trials, with continued approval
  • Ascendis scores FDA approval for weekly dwarfism drug
    Created using Ascendis' drug delivery technology for large-molecule drugs, Yuviwel (navepegritide) has been cleared to treat children aged two and over with achondroplasia, the most common form of
  • Ascendis to Showcase Advances in Treatment of Rare Endocrine . . .
    About Achondroplasia Achondroplasia is a rare genetic condition arising from a systemic fibroblast growth factor receptor 3 (FGFR3) variant that leads to an imbalance in the effects of the FGFR3 and CNP signaling pathways, estimated to affect more than 250,000 people worldwide
  • FDA approves drug for pediatric patients with most common . . .
    The U S Food and Drug Administration (FDA) has approved Yuviwel (navepegritide) for injection to improve growth in pediatric patients aged two years and older with achondroplasia (the most common
  • FDA approves once-weekly medication to increase . . . - Healio
    The FDA has approved a once-weekly therapy to improve growth for children aged 2 years and older with achondroplasia, according to an industry press release Navepegritide (Yuviwel, Ascendis Pharma
  • Achondroplasia treatment options - Medical News Today
    Achondroplasia is a common form of short-limbed dwarfism Learn about the goals of treatment, how to manage complications, and what new therapies researchers are developing
  • Achondroplasia Medication: C-Type Natriuretic Peptides - Medscape
    Medication: The skeletal dysplasias are a heterogeneous group of disorders characterized by intrinsic abnormalities in the growth and or remodeling of cartilage and bone These dysplasias affect the skull, spine, and extremities in varying degrees





中文字典-英文字典  2005-2009